E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ART-treated and ART-naïve HIV-infected adults (ART: anti-retroviral therapy) |
|
E.1.1.1 | Medical condition in easily understood language |
ART-treated and ART-naïve HIV-infected adults (ART: anti-retroviral therapy) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020161 |
E.1.2 | Term | HIV infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To assess the health status of HIV-infected persons who have been previously
enrolled in studies evaluating the F4co/AS01B vaccine
• To assess CD4 count and viral load kinetics of HIV-infected persons who have been previously enrolled in studies evaluating the F4co/AS01B vaccine
• To assess time to (re)initiation of ART of HIV-infected persons who have been
previously enrolled in studies evaluating the F4co/AS01B vaccine
• To assess the incidence of specific clinical events (cardiovascular, end stage renal
and hepatic events, opportunistic infections, cancers) of HIV-infected persons who
have been previously enrolled in studies evaluating the F4co/AS01B vaccine
• To evaluate the safety of the F4co/AS01B vaccine and to check the
safety of study participation |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the HIV-specific cellular and humoral immune responses of HIV-infected persons who have been previously enrolled in studies evaluating the F4co/AS01B vaccine
• To explore associations between health status and HIV-specific immune responses
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All subjects must satisfy ALL the following criteria at study entry:
• HIV-infected subject
• Previous participation in a study evaluating F4co/AS01B vaccine
• Written informed consent obtained from the subject
|
|
E.4 | Principal exclusion criteria |
• Subjects who did not receive a complete vaccination course in the previous study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Occurrence of ART (re)-initiation or ART modification, and reason (for ART modification)
• CD4 count
• VL and method of measurement
• Occurrence of HIV disease progression
• Occurrence of each separate defining condition for HIV-disease progression
• Occurrence of specific clinical events and death and date
• Occurrence of adverse events (AEs) or serious adverse events (SAEs)
considered by the Investigator to be related to vaccination (performed in
the preceding vaccination study)
• Occurrence of potential immune-mediated diseases (pIMDs)
• Occurrence of SAEs related to study participation |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•Time between dose 1 and ART (re)-initiation or ART modification
•Time between dose 1 and CD4 count measurement
•Time between dose 1 and viral load measurement
•Time between dose 1 and occurrence of HIV disease progression
•Time between dose 1 and occurrence of each separate defining condition for HIV-disease progression
•Antibody concentrations to vaccine antigens
•CMI responses (ICS)
Breadth
Intensity
Cytokine co-expression profile
•Additional exploratory immuno endpoints (other T-cell immune markers or T-cell functional assays)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Lg Term safety follow-up of HIV-infected subjects who previously participated in vaccination studies |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 13 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 35 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Germany |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |